PhaseBio Pharmaceuticals, Inc.

📍 Malvern, United States🗓 Founded 2002👥 29 employees💰 Last funded Mar 2017
Biotechnology🌐 phasebio.com
Website LinkedIn
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2002
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in PhaseBio Pharmaceuticals, Inc.?
PhaseBio Pharmaceuticals, Inc. has 1 investors on record on gritt.io.
When did PhaseBio Pharmaceuticals, Inc. last raise funding?
The most recent investment in PhaseBio Pharmaceuticals, Inc. recorded on gritt.io was in March 2017.
When was PhaseBio Pharmaceuticals, Inc. founded?
PhaseBio Pharmaceuticals, Inc. was founded in 2002.
What industry is PhaseBio Pharmaceuticals, Inc. in?
PhaseBio Pharmaceuticals, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is PhaseBio Pharmaceuticals, Inc. based?
PhaseBio Pharmaceuticals, Inc. is headquartered in Malvern, United States.